Review Article
Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP
Table 3
Summary of studies of single-cycle adjuvant BEP chemotherapy.
| Study | Eligibility | Median follow-up (months) | N | Number of malignant relapses (all relapses) | Predicted relapse risk | Predicted number of relapses |
| Gilbert (RMH) [20] | 1 or 2 MRC RF | 120 | 22 | 0 (1) | 20% | 4 | Westermann (Switzerland) [21] | VI+ >50% EC | 99 | 13 29 | 1 | 30% | 13 | Albers (GCSCG) [23] | Any | 56 | 191 | 1 (2) | 26% | 50 | Tandstad [24] (SWENOTECA) | VI+ VI− | 95 | 258 255 | 7 (8) 3 (4) | 42% 12% | 108 31 | 111 study [25] | VI+ | 40 | 236 | 4 (7) | 42% | 99 | Total | | | 1004 | 16 (23)1.6% (2.3%) | | |
|
|
23/305 equals 7.5% of predicted relapses. |